University of Minnesota
https://twin-cities.umn.edu/
612-625-5000
Milestone
4.2.f

Phase 3 efficacy trials

In progress
High priority

Identify the most promising vaccine candidates from phase 2 trials and facilitate good manufacturing practice (GMP) and evaluation in phase 3 trials, such as through sponsorship in public-private partnerships.

Progress Highlights

No potentially universal or broadly protective influenza vaccines have reached phase 3 trials. However, several next-generation, improved seasonal vaccine candidates are currently in phase 3 trials.

See vaccine technology landscape